To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

April 18, 2027

Study Completion Date

July 31, 2027

Conditions
Cancer, Hepatocellular
Interventions
DIAGNOSTIC_TEST

GAAD score

In order to calculate the GAAD score an in-vitro diagnostic is used. The Elecsys GAAD assay by Roche Diagnostics is used to assess the GAAD score using on blood samples collected from patients during regular outpatient clinic visits. The Elecsys GAAD test combines the results of the Elecsys PIVKA-II and Elecsys AFP assays with gender and age (the GAAD score is calculated with PIVKA-II, AFP, gender and age).

Trial Locations (1)

Unknown

RECRUITING

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER